Matthew is a Partner based in our London office. Before joining SR One in 2011, he spent eight years at Greenhill & Co, an M&A investment banking and private equity firm in New York. Since then he has focused on solving medicine’s most challenging unmet needs, from sepsis to dementia; and developing powerful new technologies such as gene therapies for hearing loss and oncolytic viruses. More broadly Matthew is passionate about mentoring and building connections between scientists, entrepreneurs, and investors, and building world leading companies around unexploited European science.
Matthew has a BSc/MSc in Molecular Biology from the University of Oxford, Corporate Finance from London Business School and Drug Discovery from UCL
No one expects the Spanish Inquisition…or CMC issues